anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The standardized requirements for implantable cardioverter defibrillator (ICD) include defibrillation testing (DT), consisting in induction and termination of ventricular fibrillation (VF). An effective DT has historically been considered part of standard procedures at implant. Nevertheless, implant techniques and technology have evolved during years and nowadays deviations are frequent in clinical practice mainly due to the fact that physicians are seriously concerned about the risk of severe complications related to DT. However, the practice of not performing DT is arbitrary and its safety is yet unproven. This observational study will assess the safety of the two strategies adopted at ICD implant: induction (including patients who undergo DT at implant) and non-induction (including patients who do not undergo DT at implant. No deviation from the centres' current practice in choosing to perform or not perform DT is introduced by this study protocol. The study considers consecutive patients undergoing first implant of ICD
The invention relates to a cyclodextrin esterified derivative, a preparation method and an application of the cyclodextrin esterified derivative, belonging to the technical field of oil in water adjuvants. The cyclodextrin esterified derivative is obtained by esterifying cyclodextrin by lauroyl chloride and sulfuric acid. The invention further provides a preparation method of the cyclodextrin esterified derivative. The preparation method is characterized by comprising the following steps: (1) carrying out esterification reaction on cyclodextrin and acyl chloride; (2) carrying out esterification reaction on a mixture obtained after the reaction in the step (1) and chlorosulfonic acid; and (3) taking the mixture obtained after the reaction in the step (2), adjusting the pH to 6.8-7.2, removing the solvent, and dissolving, dialyzing and drying the precipitate to obtain the cyclodextrin esterified derivative. The invention further provides an oil in water adjuvant and a veterinary vaccine. The oil in water adjuvant prepared by the cyclodextrin esterified derivative has good stability and centrifugal stability, and the immunocompetence of the antigen can be remarkably improved. The preparation method of the cyclodextrin esterified derivative provided by the invention is simple, low in degree of substitution of sulfate radicals, high in degree of substitution of lauroyl and high in yield.
The present disclosure provides a lipid nanoparticle and uses of the lipid nanoparticle for treating cancer, targeting integrin [alpha]v[beta]3, anti-angiogenesis to prevent cancer metastasis and reducing the cytotoxicity of anti-cancer drugs to normal cells. In addition, since it can inhibit angiogenesis, it also can be used in vascular related diseases. The lipid nanoparticle provides targeting cell surface integrin [alpha]v[beta]3, the nano-liposome specific against digestion system-related cancers locally and systemically. The lipid nanoparticle of the present disclosure would target cancer cells instead of normal cells. Even normal cells contain integrin [alpha]v[beta]3, however, the lipid nanoparticle of the present disclosure only recognizes the conformation of integrin [alpha]v[beta]3 on the cancer cells. The lipid nanoparticle of the present disclosure can equip with other targeting molecules, payload with other anti-cancer drugs, and can combine with radiation therapy and reduce radiation therapeutic threshold.
This is an open-label (volunteer and study staff will know the identity of the assigned treatment) study of two abiraterone acetate suspension formulations, compared to the abiraterone acetate tablet formulation in healthy volunteers. Approximately 30 healthy volunteers will participate in this study. Each volunteer will be randomly assigned to 1 of 6 possible treatment sequences. The study consists of a screening phase (within 21 days before the first study drug administration of the first period); an open-label treatment phase consisting of 3 single dose treatment periods; and end-of-study or withdrawal assessments done upon completion of the 72-hour (Day 4 of Period 3, or upon withdrawal) sampling to evaluate how the drug is absorbed in the body, distributed within the body, and how it is removed from the body over time. A 7- to 14-day washout period will separate the study drug administrations. The duration of participation in the study for an individual healthy volunteer will be from 41 days to a maximum of 55 days (including screening). Safety will be monitored. Volunteers will receive a 250 mg dose of abiraterone acetate as a tablet, suspension Formulation 1, and suspension Formulation 2 according to their treatment sequence. Abiraterone acetate tablets must be swallowed whole and not chewed, divided, dissolved or crushed and will be taken with 240 mL of noncarbonated water. For the suspensions, the volunteer will drink the contents of the vial. The vial will be rinsed with 10 mL of water, and the volunteer will be asked to drink the rinse water.
VENTAVIS is intended to be inhaled using the I-neb® AAD® System. The recommended initial inhaled dose is 2.5 mcg (as delivered at the mouthpiece). If well tolerated, increase dosing to 5.0 mcg and maintain at that dose; otherwise maintain the dose at 2.5 mcg [see Warnings and Precautions (5.1)]. VENTAVIS should be taken 6 to 9 times per day (no more than once every 2 hours) during waking hours, according to individual need and tolerability. The maximum daily dose evaluated in clinical studies was 45 mcg (5 mcg 9 times per day). 

Direct mixing of VENTAVIS with other medications in the I-neb® AAD® System has not been evaluated; do not mix with other medications. To avoid potential interruptions in drug delivery due to equipment malfunctions, the patient should have easy access to a back-up I-neb®AAD® System.

For each inhalation session, only a mouthpiece should be used. Avoid skin or eye contact with VENTAVIS solution. Do not orally ingest VENTAVIS solution. 

VENTAVIS is supplied in 1 mL ampules in two concentrations: 10 mcg/mL and 20 mcg/mL.

The 20 mcg/mL concentration is intended for patients who are maintained at the 5 mcg dose and who have repeatedly experienced extended treatment times which could result in incomplete dosing. Transitioning patients to the 20 mcg/mL concentration using the I-neb® AAD® System will decrease treatment times to help maintain patient compliance.

For each inhalation session, the entire contents of each opened ampule of VENTAVIS should be transferred into the I-neb® AAD® System medication chamber immediately before use. Discard any solution remaining in the medication chamber after each inhalation session. Patients should follow the manufacturer's instructions for cleaning the I-neb® AAD® System components after each dose administration.
A stable product containing an aqueous solution of one or more carotenoids for use in supplementing aqueous systems, such as foods, beverages, dietary supplements, and personal care products, with the carotenoid. An ester is dissolved in water and a source of the carotenoid is added to the solution. The concentrated product may be added to the aqueous systems or dried to form a powder that is readily dispersible in aqueous systems. The product may also include an antioxidant to preserve the activity of the carotenoid. Esters particularly suited for use include sucrose fatty acid esters. The product is produced without the use of organic solvents or elevated temperatures. The particles of carotenoids dispersed in the liquid form of the product will pass through a 0.2 micron (μm) sterile filter.
Objective: To observe the characteristics and differences of gut microbiota in asthma patients with different inflammatory types through metagenomic analysis. Methods: Adults aged ≥18 years who visited the Respiratory Clinic of Peking University Third Hospital from August 1, 2021 to August 31, 2022 and were primarily diagnosed with asthma were selected as the study subjects. Finally, 29 patients with stable asthma were included. Fresh fecal samples were collected and the fecal DNA was extracted for high-throughput 16sRNA sequencing of gut microbiota. The diversity and community structure of gut microbiota in different groups of asthma patients were compared, and the species differences were analyzed through random forest and LEfSe analysis. Results: There were sex-based differences in asthma patients with different types of inflammation, and the proportion of female patients was higher in neutrophilic asthma patients (χ2=4.14, P=0.042). There was no significant intergroup difference in the alpha diversity of gut microbiota among asthma patients with different inflammatory types, but there were significant differences in the microbiome. Patients with neutrophilic asthma had higher relative abundance of Bacillales (P=0.029) and Oscillospiraceae (P=0.015). In species LEfSe analysis, patients with eosinophilic asthma had a higher relative abundance of fungi. Conclusion: There are intergroup differences in the gut microbiota of asthma patients with different inflammation types, and fungi are biomarkers that distinguish the differences in gut microbiota between patients with eosinophilic asthma and neutrophilic asthma.
The OMEGA-PAD II trial will be a 1:1 randomized, double-blinded trial comparing oral supplementation of n-3 PUFA (4.4g/day) to placebo in claudicants (Rutherford stage 1-3) for 3 months. Eligible patients will be screened according to specified inclusion and exclusion criteria. All patients will be treated per our current practice as reflected in the American Heart Association Practice guidelines on PAD. Blood draws, vascular function testing and 6-minute walking tests will be performed at baseline and after 3 months. n-3 PUFA supplementation will be achieved with 4 capsules of Pro-Omega twice daily (Nordic Naturals, Watsonville, California, USA), corresponding to a total of 4.4g/day. Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. The placebo group will take the same number of capsules containing inactive substance (soybean; Nordic Naturals), designed to be the same color and shape as the treatment capsules.
PURPOSE:To obtain a low-toxic cariostatic agent effective in inhibiting the growth of Streptococcus mutans which is a main cariogenic bacterium and exhibiting excellent antibacterial and remedying effects, by using a specific cyclic compound derivative as an active component. CONSTITUTION:The objective agent contains one or more cyclic compound derivatives of formula (A is -CH2- or -O-; B is -CO- or -CH2; n is 8-18) as active components. The compound of formula is e.g. tetradecanoyl-piperidine, tetradecyl-piperidine and its hydrochloride, hexadecyl-piperidine and its hydrochloride, octadecyl-piperidine and its hydrochloride or hexadecanoyl-morpholine. It can be used in various forms of conventional agent including dental antibacterial agent, dentifrice for preventing dental caries, etc. The compound of formula can be produced e.g. by acylating piperidine with an acid chloride.
The invention discloses an external medicament for treating vitligo. The external medicament consists of an ointment A and a liniment B. Major ingredients of the external medicament comprise suberect spatholobus stem, malaytea scurfpea fruit, dark plum fruit, wild celery, red-rooted salvia root and the like. The external medicament has the effects of nourishing liver and kidney, promoting blood circulation, removing obstruction in channels, expelling the wind and removing ecchymoses. The medicament is different from the conventional treatment scheme for merely treating vitligo. A 'day and night double-circulation therapy' is initiated for the first time, and 24-hour uninterrupted administration is performed. At night, the ointment A is used for changing a surface infection pathologic change epidermic tissue structure, so that smoothness of a medicament permeation channel is facilitated, the medicament directly reaches focus tissues, the skin black cell activity is increased quickly, and tyrosinase is activated for accelerating quick melanin synthesis; and during the day, the liniment B is applied, so that various active ingredients and trace elements are supplemented, the photosensitization is enhanced for facilitating the melanogenesis, vitligo pathogenic factors are eliminated quickly and completely, the black cell function is improved, skin melanin is protected and accumulated, and relapse is avoided. The external medicament has the advantages of multiple three-dimensional layers, treatment of both principal and secondary aspects of a disease, unique therapy and reliable curative effect.
PURPOSE: Long-term surgical outcomes were compared between bilateral lateral rectus recession (BLR) and unilateral lateral rectus recession combined with medial rectus resection in the same eye (R&R) for therapy of basic type intermittent exotropia (IXT) with equal dominance.
METHODS: Two hundred and sixty-eight subjects (3-11 years old) with basic IXT with equal dominance who underwent BLR or R&R surgery were enrolled to this study, and with a minimum follow-up period of 18 months. One hundred and fourteen patients underwent BLR surgery and 144 underwent R&R surgery at a single centre. Surgical outcomes between groups were compared. Surgery results were divided into 3 categories: undercorrection/recurrence (exotropia/phoriaå 10PD), success(esotropia/phoria ≤5PD to exotropia/phoria≤10PD), and overcorrection (esotropia/phoriaå 5 PD) according to postoperative deviation angle.
RESULTS: No statistical difference was detected between BLR group and R&R group at all intervals with the exception of the last examination, demonstrating a higher success rate and a lower recurrence rate in the BLR group than R&R group at last visit (P = 0.04). Additionally, the BLR group demonstrated a smaller exodrift than the R&R group at distance and near fixation (P = 0.01; P = 0.03). Stereoacuity and exotropia control showed overall improvement following both surgeries, and this improvement had no statistical difference between groups(P > 0.05).
CONCLUSIONS: BLR showed better long-term results than R&R in the treatment of basic type intermittent exotropia with equal dominance given its low recurrence rate. Both BLR and R&R surgeries could improve stereoacuity function and exotropia control, and to same extents.
NEW MATERIAL:A quinazoline derivative shown by the formula I (R is lower alkyl, lower alkoxy, or halogen) or its acid addition salt. EXAMPLE:2-Fluoromethyl-3-(2-methyl-4-chlorohenyl)-6-amino-4(3H)-quinaz oline. USE:A muscle relaxant. Showing stronger muscle relaxing action and higher safety and well-known muscle relaxant (e.g., mephenesin). PREPARATION:A compound shown by the formula II is condensed with a fluoroacetic acid shown by the formula III in a proper solvent in the presence of a dehydrating agent (e.g., dicyclohexylcarbodiimide) at 15-100 deg.C to give a compound shown by the formula IV. The compound shown by the formula IV is subjected to intramolecular ring formation in a proper solvent in the presence of boron trifluoride ether complex at 90-120 deg.C, and reduced to give a compound shown by the formula I .
The toxicological profile for aripiprazole administered to experimental animals by intramuscular injection is generally similar to that seen following oral administration at comparable plasma levels of the drug. In dogs, repeated intramuscular dosing of the 2-month aripiprazole extended release injectable suspension over a period of 52 weeks produced no clinical evidence of significant local irritation, and resulted in slight foreign-body type of localized granulomatous inflammatory reaction to deposited drug at the injection site. These effects gradually resolved with discontinuation of dosing.

Oral aripiprazole produced retinal degeneration in albino rats in a 26-week chronic toxicity study at a dose of 60 mg/kg and in a 2-year carcinogenicity study at doses of 40 and 60 mg/kg. The 40 and 60 mg/kg/day doses are 13 and 19 times the maximum recommended human oral dose (MRHD) based on mg/m2 body surface and 7 to 14 times human exposure at the oral MRHD based on AUC. Evaluation of the retinas of albino mice and of monkeys did not reveal evidence of retinal degeneration. Additional studies to further evaluate the mechanism have not been performed. The relevance of this finding to human risk is unknown.
prospective, randomized, single-blind study comparing two groups of patients treated with aerosolised (AS) colistin versus colistin intravenously (IV). Included were patients who have mechanical ventilation over 48 hours and that have developed a VAP. A VAP was defined as a CPIS (Clinical Pulmonary Infection Score) \>6. Exclusion criteria were septic shock and/or bacteraemia. Included patients were divided into two randomized groups. The 1st received colistin in AS as 4 MU by nebulisation 3 times per 24 h. The 2nd received colistin in IV as a loading dose of 9 MU followed by 4.5MU two times per 24 h. Colistin was given for 14 days or until extubation. Patients were followed for 28 days. Therapeutic efficacy was assessed by a primary outcome: the cure of VAP at day 14 of therapy and defined as resolution of clinical and biological signs of infection that means a CPIS\< 6 and bacteriological eradication. Secondary outcomes: duration of mechanical ventilation, ICU stay-length and mortality at day 28. Systemic toxicity was assessed by the occurrence of acute renal failure (ARF) defined as increase of plasma creatinine more than 1.5 times its base value.
PROBLEM TO BE SOLVED: To obtain the subject new compound, useful as. e.g. a percutaneous absorption accelerator having excellent percutaneous absorption effects on medicines and low in irritancy and toxicity to the skin, and exhibiting effective actions on many medicines, by including a specific organosiloxane having succharide residues. SOLUTION: This compound is a new organosiloxane compound having succharide residues and expressed by formula I [R is H or an acyl; X is O or S; R<1> to R<4> are each a 1-6C alkyl; R<5> is a 1-20C alkyl; (n) is 0, 1, or 2; (p) is an integer of 3 to 6; (m) is an integer of >=1] and useful as, e.g. a percutaneous absorption accelerator which has excellent percutaneous absorption effects on medicines and is low in irritancy and toxicity to the skin and exhibits effective actions on many medicines. This compound is obtained by reacting a saccharide derivative having an alkenyl group expressed by formula II (R' is an acyl) with a siloxane compound having Si-H bond at one terminal and expressed by formula III, in the presence of a catalyst for hydrosilylation, and then, as necessary, eliminating the acyl groups.
PROBLEM TO BE SOLVED: To obtain a washing-away-after-application type composition showing a transparent gel-like appearance in spite of containing a small soap content, good in storing stability, high in safety, capable of adjusting its cleaning power by using two kinds of specific materials with the soap simultaneously. SOLUTION: This transparent get-like composition is prepared by using a swelling clay mineral and a cellulose-based weakly anionic water soluble polymer combined with a soap. As the swelling clay mineral, natural or synthetic smectites are preferable and their amount of blending are approximately 0.01-5wt.%. As a part or all of the cellulose-based weakly anionic water soluble polymer, a carboxyalkylcellulose salt (especially a sodium salt) is preferable, and its amount of blending is approximately 0.01-5wt.%. As the soap, i.e.,) a fatty acid soap component, potassium laurate, etc. are cited, and its amount of blending is preferably <=20wt.% in view of its safety, especially <=10wt.%. This composition has a refreshing feeling of its use specific to the soap after washing it away and a low stimulating property.
According to grouping，patients were premeditated with injection of Propofol 2-2.5mg / kg IV . If BIS is ≤ 60, Tracheal intubation was facilitated with cisatracurium 0.2mg/kg a IV and sufentanil 0.3 μ g / kg IV. if BIS is \>60, propofol 1mg/kg was titrated intravenously, with an interval of more than 1min until the BIS is ≤ 60，and intubation was performed after cisatracurium and sufentanil injected .General anesthesia was maintained with Propofol and remifentanil.Then propofol was maintained in group P at 4-12 mg/kg/h and remifentanil was maintained at 0.1-0.3 ug/kg/min .BIS was kept at 40 \~ 60 during the surgery, and infusion drugs were stopped at the end of the operation. The patients were Transfered to Postanesthesia care unit(PACU) after the operation.
Compositions based on amino acids are described, in particular for oral or parenteral use, suitable for treating heart insufficiency. The conpositions according to the invention comprise up to 75% of the branched chain amino acids leucine, isoleucine and valine, as active ingredients. Preferably, the compositions also comprise, as further active ingredients, up to 50% of threonine and lysine. Other essential amino acids are preferably also provided (in particular methionine, phenylalanine, histidine, triphtophan) as well as non essential amino acids (in particular tyrosine and/or cyst(e)ine-i.e. cystine and cyst(e)ine). Other amino acids can be added, provided that their sum is in a percentage being lower than 20% with respect to the other active ingredients, and less than 10% for each single amino acid.
Fuel and incoming air (10) are mixed in the combustion chamber of a gas turbine and then burnt. The combustion air flow is then fed to a turbine downstream of the combustion chamber. The chamber has a ring-shaped diffuser (13), in which the air current enters. Downstream of the diffuser and connected to it is at least one ring-shaped toroidal chamber (14).  Downstream of the toroidal chamber mixture tubes (22) branch away and are distributed over its periphery. Downstream of the mixture tubes a combustion chamber (18) is arranged, in which the mixture tubes issue. The combustion chamber is formed as a secondary unit. The turbine has a primary combustion chamber, downstream of which is a first turbine (11), a secondary combustion chamber downstream of the first turbine and a second turbine functioning downstream of the secondary combustion chamber.
Chronic Kidney Disease (CKD) is a significant global health issue that leads to end-stage renal disease (ESRD) and is associated with rising healthcare costs and high mortality rates. Its prevalence is increasing due to aging populations and the growing rates of diabetes and hypertension. CKD causes severe complications and significantly impairs patients' quality of life. There are notable disparities in CKD incidence and treatment among different socioeconomic groups, and many healthcare systems struggle with the challenges of managing and funding the disease.

In terms of treatment, there is a particular bottleneck in addressing CKD among non-diabetic patients. Currently, the focus for non-diabetic CKD patients is on controlling blood pressure and proteinuria. However, new treatments such as finerenone show promise in reducing CKD progression and cardiovascular risks in diabetic patients. Ongoing research aims to explore the effectiveness of these treatments in non-diabetic CKD patients as well. It is important to note that further studies are required to confirm the safety and efficacy of finerenone in these specific populations.
PROBLEM TO BE SOLVED: To obtain an agent useful for the prevention and treatment of diseases causing the fracture and degeneration of articular cartilage tissue such as osteoarthrosis. SOLUTION: This agent contains a parathyroid hormone relating peptide (PTHrP) or a PTHrP-originated substance (e.g. 1-34 PTHrP) as an active component. The PTHrP is preferably e.g. a human PTHrP composed of 141 amino acids and the human 1-34 PTHrP of the PTHrP-originated substance is a partial peptide of a PTHrP composed of 34 amino acids from the N-terminal to the 34th amino acid of PTHrP. The administration dose of PTHrP is e.g. 10<-20> to 10<-5> M, preferably 10<-15> to 10<-7> M in tissue level by topical injection into the articular cavity or the lesion.